The study led by academics and paediatricians at the University of Bristol and Bristol Royal Hospital for Children is published in Cell Reports Medicine.

 

During the pandemic, children have been much less likely to become seriously ill with COVID-19, which is unexpected, especially in young infants who are known to be vulnerable to severe disease from other respiratory viruses, such as RSV (respiratory syncytial virus) and flu.

 

Early in the pandemic, it became evident young infants with COVID-19 who were being cared for by paediatricians at the Bristol Royal Hospital for Children were only mildly affected by the disease.

 

With very little data published on the immune response to SARS-CoV-2 in young babies, the research team set out to examine antibody and cellular immune responses to SARS-CoV-2 in young infants compared with adults.

 

Dr Anu Goenka, Clinical Lecturer in Paediatric Infectious Diseases and Immunology at the University of Bristol and Bristol Royal Hospital for Children, said: “By conducting a detailed study on young infants who are relatively protected from severe COVID-19, we have shown what protective immunity 'looks like’, in terms of the make-up of specific antibodies and immune cells directed against SARS-CoV-2.

“This is very useful information for the design of future COVID-19 vaccines that could seek to induce and mimic the signature of this protective immunity.”

The work was supported by Wallace and Gromit's Grand Appeal, the dedicated charity for the children’s hospital, the Elizabeth Blackwell Institute, Wellcome and UKRI.

Paper

‘Young infants exhibit robust functional antibody responses and restrained IFN-γ production to SARS-CoV-2’ by Anu Goenka et al in Cell Reports Medicine [open access]

For the full story visit the University of Bristol website.